CORRECTING and REPLACING: Pharmasimple Announces Its Decision to Acquire an Equity Stake in Phytocann Group
Headline of release dated August 16, 2022, should read: Pharmasimple Announces Its Decision to Acquire an Equity Stake in Phytocann Group (instead of Phytocann Group announces its acquisition of a stake in Pharmasimple). Also, first sentence of second paragraph should read: Pharmasimple is delighted to acquire a 5% equity stake in Phytocann Group for the sum of 5 million euros (instead of Phytocann Group is delighted to acquire a 5% stake in Pharmasimple for the sum of 5 million euros).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005631/en/
The updated release reads:
PHARMASIMPLE ANNOUNCES ITS DECISION TO ACQUIRE AN EQUITY STAKE IN PHYTOCANN GROUP
Phytocann Group, a vertically integrated company and European CBD pioneer, is proud to announce a partnership with Pharmasimple, a company listed on Euronext Growth Paris and industry leader in Belgium. This strategic rapprochement opens up a new era for the distribution of cannabic products in pharmacies.
Pharmasimple is delighted to acquire a 5% equity stake in Phytocann Group for the sum of 5 million euros. Beyond the additional skills and expertise, this increase in capital lays the foundations for a medium-term IPO.
The research and development component is also particularly important. New ranges and the launch of new products are already being explored by the two entities. As a long-standing online pharmacy leader, Pharmasimple has been undergoing a business transformation for several months by diversifying its network of physical pharmacies. Having set itself the goal of 200 by 2025, 14 are already open and 15 are scheduled to open in 2022.
This strategic partnership will lead to the introduction of a range of unique products dedicated to Pharmasimple, including CBD oils and cosmetics. It should be noted that the brands belonging to Phytocann Group (Harvest Laboratoires, Ivory, Easy Weed, Herboristerie Alexandra etc.) will be distributed both in shops and on the Pharmasimple website.
As online sales of CBD are of crucial importance to Phytocann Group, this partnership will enable us to create shared synergies and thus to step up and expand our online presence. Always striving to create and offer outstanding products, research and tests are being carried out on new product innovations based on CBD and other non-psychotropic cannabinoids.
This capital acquisition takes advantage of the best possible timing regarding the expansion of Phytocann Group and the opening up of the medicinal cannabis market in Europe, a sign of real added value for Pharmasimple.
Distribution in pharmacies and drugstores was a major challenge. This also strengthens the positioning and the DNA of a 100% vertically integrated group, from production to sales.
If you would like any further information or an interview with a leader of Phytocann Group, don’t hesitate to contact the press office: email@example.com
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Samuel BOTTON: +33 (0)6 84 79 99 61 – firstname.lastname@example.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AGIC Capital Acquires Majority Stake in ATEC Pharmatechnik GmbH30.11.2022 08:00:00 CET | Press release
AGIC Capital ("AGIC"), a growth-oriented private equity firm with $2.2 billion of assets under management, today announced that it had acquired a majority stake in ATEC Pharmatechnik GmbH ("ATEC" or "the Company"). The sellers, ATEC’s founder & CEO, Hans-Werner Mumm, and family-backed Mittelstand investor HANNOVER Finanz Group, will remain invested in the Company, and Hans-Werner Mumm will continue to act as its CEO. ATEC is a leading manufacturer of aseptic processing solutions, primarily used in pharmaceutical manufacturing and bioprocessing applications, with a customer base that includes the top 10 global pharmaceutical companies. ATEC's products include stopper and cap processing systems used for aseptic filling, RTP transfer ports and ancillary single-use transfer bag solutions. These mission-critical technologies enable ATEC's customers to establish safe and reliable manufacturing process environments. This is anticipated to be the first of several acquisitions as AGIC builds a
New Prospective Study Finds That Masimo SpHb ® Noninvasive and Continuous Hemoglobin Monitoring Can Help Provide Effective Blood Management in Patients Undergoing Major Surgery30.11.2022 08:00:00 CET | Press release
Masimo (NASDAQ: MASI) today announced the findings of a prospective, double-blinded, randomized, controlled trial published in the Journal of the College of Physicians and Surgeons Pakistan. In the study, Dr. Sukriye Akdag and colleagues at Marmara University in Istanbul, Turkey assessed the impact of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® on blood transfusion management for adult patients undergoing elective major surgery with anticipated blood loss of 20% or more. The researchers found that the postoperative red blood cell (RBC) transfusion rate was lower, and the hemoglobin level of ICU patients higher, when monitored with SpHb in the operating room. They concluded, “SpHb can provide effective patient blood management in cases of major surgery.”1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129006160/en/ Masimo Root® with SpHb® and PVi® (Photo: Business Wire) Noting that delayed or unneces
New survey reveals API strategies, concerns as enterprises look to securely free data for business growth30.11.2022 08:00:00 CET | Press release
Axway (Euronext: AXW.PA), a leading provider of API management and integration software, today announced new data from its inaugural 2022 Open Everything Strategy Survey Report. Polling nearly 1,000 IT leaders, architects, and developers about their digital strategies and top concerns, the survey found nearly 40% of organizations are in the process of adopting a new hybrid approach for their IT infrastructure. The transformation comes as 68% of respondents cite their fears about API sprawl. The survey data reflects responses from those engaged primarily in API development (893) and managed file transfer (MFT) services (102). Ensuring data security and controlling API sprawl were top concerns, with over two-thirds (68%) worrying about complexity due to sprawl and almost half (48%) of respondents ranking “increased security challenges” as their single greatest concern with API growth. Respondents again cited security as far and away the most important criteria when creating an API (30% a
Illumination and Nintendo Announce Second Trailer and the Japanese voice cast for The Super Mario Bros. Movie29.11.2022 23:44:00 CET | Press release
Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced the second trailer for The Super Mario Bros. Movie, the new animated film based on the world of Super Mario Bros. during the Nintendo Direct which was streamed today. In addition, the two companies announced the Japanese voice actors for the characters Mario, Princess Peach, Luigi, Bowser, and Toad. Japanese voice cast Mario Mamoru Miyano Princess Peach Arisa Shida Luigi Tasuku Hatanaka Bowser Kenta Miyake Toad Tomokazu Seki About The Super Mario Bros. Movie, the Super Mario Bros. animated film The Super Mario Bros. animated film, produced by Chris Meledandri of Illumination and Shigeru Miyamoto of Nintendo, will be co-financed by Universal Pictures and Nintendo, and released worldwide by Universal Pictures. Directed by Aaron Horvath and Michael Jelenic (collaborat
Access Advance Announces Initial VVC Advance Patent List29.11.2022 19:31:00 CET | Press release
Access Advance today posted the initial patent list for its VVC Advance Patent Pool (https://accessadvance.com/vvc-advance-patent-list/). The initial patent list includes over 700 VVC standard essential patents (SEPs) issued in sixty-one countries that were independently determined to be essential to the VVC/H.266 Standard. With thirty-three VVC Advance Licensors currently, the size of the VVC Advance patent list is expected to grow substantially as additional VVC SEPs issue and are evaluated, and as additional Licensors join the VVC Advance Patent Pool. As with the HEVC Advance Patent Pool, the VVC Advance Patent Portfolio License (“PPL”) includes all VVC SEPs, current and future, that the program’s Licensors have the right to license, regardless of whether the patents are specifically included in the patent list. This assures that compliant Licensees are licensed to all VVC Advance Licensors’ VVC SEP claims under the terms of the PPL when a patent with VVC essential claims issues, ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom